Should I Buy Seres Therapeutics Stock in 2025? UAE Investors’ Guide

What is Seres Therapeutics?

How much is the Seres Therapeutics stock?

The price of Seres Therapeutics stock is falling this week. As of now, MCRB trades at $7.09, with a 24-hour increase of $0.04 (+0.57%) but a 7.92% decrease over the past week.

There is currently no P/E ratio or dividend yield, as Seres reports ongoing losses and pays no dividends. The stock beta is 2.88, highlighting significant volatility—an important aspect to consider for investors in the UAE seeking dynamic opportunities in the biotech sector.

Our full analysis on the Seres Therapeutics stock

We have thoroughly reviewed Seres Therapeutics’ most recent financial results and examined the stock’s evolution over the last three years, integrating a breadth of proprietary analysis across financial metrics, technical indicators, peer comparisons, and broader market signals. Our holistic approach reveals a nuanced picture of a company in the midst of remarkable innovation and strategic repositioning. So, why might Seres Therapeutics stock once again become a strategic entry point into the emerging field of microbiome therapeutics in 2025?

Recent Performance and Market Context

Seres Therapeutics (NASDAQ: MCRB) has experienced a pronounced correction over the past twelve months, with the stock now trading at $7.09, down approximately 62% over the past year and 64% in the last six months. Despite these declines, the recent stabilization near its 52-week low at $6.53 has attracted a new cohort of value-oriented investors.

This drawdown masks a series of constructive underlying developments:

• Breakthrough Therapy Designation from the FDA, awarded in December 2024 for SER-155, flags exceptional promise in the high-value area of infection prevention for stem cell transplantation patients.
• Completion of a strategic asset sale to Nestlé in January 2025, bringing in $50 million in non-dilutive capital and further $25 million expected by July 2025.
• Strong net profit in Q1 2025 (+$32.7 million vs. a loss of $32.9 million prior), reflecting prudent management and value realization on the company’s first-in-class product portfolio.
• Moderate trading volumes (average 88,612 shares/day over 3 months) with a $61.9 million market cap, signaling continued market engagement.

On the macro level, renewed investor appetite for innovative biotech and favorable US regulatory momentum have combined with increased global health system attention to infectious disease risks. These themes are particularly resonant in the GCC region, where demand for biotech innovation—and exposure to next-generation healthcare—is on the rise.

Technical Analysis

From a technical standpoint, Seres Therapeutics appears to be carving a compelling long-term base:

• RSI (14 days) at 39.20 suggests the stock is entering oversold territory—often a precursor for bullish reversals, especially after extended drawdowns.
• MACD at -0.78 and trading below all major moving averages (20D at $7.83; 50D at $10.16; 100D at $13.00; 200D at $15.05) confirm a downtrend, but also point towards capitulation—a classic phenomenon ahead of trend reversals.
• Key technical support at $6.53 has been robustly defended. Should this level hold, the probability of an upward retracement increases.
• 52-week resistance at $30.60 offers a clear longer-term target, with ample room for appreciation should positive catalysts materialize.

While current technicals reflect prior bearish pressure, a bottoming process appears underway. Historically, such extended consolidations—especially near pivotal supports—often precede sharp upward re-ratings in innovative biotech sectors.

Fundamental Analysis

Seres Therapeutics is in a rigorous phase of clinical development and transformation after the pivotal sale of VOWST to Nestlé:

• Revenues: No recurring operating revenue presently, but the $50 million upfront from asset divestiture demonstrates monetization capacity of internal innovations.
• Profitability: Q1 2025 net income of $32.7 million (versus the prior year’s $32.9 million loss) delivers an emphatic proof point for management’s ability to unlock value despite early-stage clinical focus.
• Valuation: With a current market capitalization below $62 million and innovative assets in its pipeline, Seres presents an unusually attractive risk/reward profile, tradeable at a notable discount to historic biotech M&A valuations.
• Structural strengths:
• Innovation leadership: Seres was the first to bring a live microbiome product (VOWST) through regulatory approval and commercial exit, confirming strong R&D and partnering credentials.
• Unique competitive moat: Scientific leadership in microbiome biotherapeutics, strengthened by a robust intellectual property portfolio, and new FDA Breakthrough Therapy designation for SER-155.
• Strategic expansion: The current pipeline focuses on high-need indications with clear regulatory and commercial paths, enhancing asymmetric upside potential.

This combination of proprietary science, recent cash inflows, and validated clinical programs establishes a solid footing, suggesting Seres’ valuation could be recalibrated as pipeline execution advances.

Volume and Liquidity

Liquidity remains solid, especially considering the company’s post-split float (8.73 million shares outstanding):

• Sustained trading volumes (88,612 average daily) suggest that despite recent volatility, institutional and sophisticated market participants remain engaged.
• Friction of a relatively tight float amplifies price moves—both up and down—creating latent conditions for dynamic upside re-ratings should sentiment and catalysts turn favorable.

Such volume patterns typically signify underlying institutional monitoring. For investors seeking nimble, high-beta exposure, this dynamic provides a favorable backdrop for tactical trading as well as strategic positioning.

Catalysts and Positive Outlook

Several compelling catalysts are aligned for the second half of 2025 and beyond:

• SER-155 Phase 2 clinical protocol submission is imminent, with FDA Breakthrough Therapy status accelerating development timelines.
• Potential strategic partnerships expected to bring non-dilutive capital and expanded clinical reach.
• $25 million milestone payment due from Nestlé in July 2025, extending the operational “runway” well into Q1 2026.
• Expansion into new patient populations: The clinical program targets a range of highly vulnerable, underserved groups—expanding addressable markets significantly.
• Ongoing advances in biomarker-driven innovation, presented at high-profile industry events such as ASCO, have further elevated Seres’ scientific profile.

On a sector level, sustained biotech rebound and increasing focus on personalized and living medicines illuminate a uniquely supportive macro-context. Strengthened regulatory clarity for live biotherapeutics, particularly in the U.S. and Emirates healthcare systems, bolsters visibility for Seres’ pipeline.

Investment Strategies

Several approaches appear particularly well suited for Seres Therapeutics at this pivotal juncture:

• Short-term traders may find attractive risk/reward in positioning near strong technical support at $6.53, with manageable stop-loss placement.
• Medium-term investors could accumulate through Q2 and Q3 2025, ahead of multiple pipeline readouts and pending non-dilutive capital injections.
• Long-term holders gain exposure to a company with proven innovation, a differentiated pipeline, and outstanding prospects for industry partnerships or future M&A. Entry at 60%+ below prior 12-month highs offers compelling margin of safety.

For those seeking to build positions ahead of major catalysts or potential inflection points within the biotech sector, Seres stands out as a high-conviction candidate for consideration.

Is it the Right Time to Buy Seres Therapeutics?

Seres Therapeutics stands at a powerful inflection point in its corporate journey—anchored by recent FDA recognition, a portfolio of first-in-class programs, demonstrated strategic execution, and an emerging, capital-efficient operating model. The stock’s current technical positioning near multi-year lows, coupled with upcoming fundamental and clinical catalysts, sets an optimal stage for renewed institutional and retail interest.

The fundamentals justify renewed attention. With its unique positioning at the forefront of microbiome innovation, the company is poised to benefit from accelerating sectoral momentum and strategic capital inflows. The stock’s current discount to both historic and peer valuations may be unsustainable should pipeline progress and partnership momentum continue.

For investors in the UAE and across international markets who seek early exposure to next-generation healthcare innovation—while maintaining an appreciation for measured risk—Seres Therapeutics seems to represent an excellent opportunity at these levels. The pipeline strength, near-term milestone payments, and robust clinical momentum suggest the stock may be entering a new bullish phase, with material upside potential as evidence continues to build.

In a market increasingly focused on breakthrough therapeutics and tangible patient impact, Seres Therapeutics positions itself as a differentiated contender worthy of close and proactive attention by forward-looking investors.

How to buy Seres Therapeutics stock in the UAE?

Buying shares of Seres Therapeutics (NASDAQ: MCRB) online is straightforward, secure, and accessible for investors in the UAE. All you need is an account with a reputable, regulated broker offering US stock market access. You can either buy the stock directly (“spot” or cash buying) or trade on price movements via Contracts for Difference (CFDs). Both methods offer flexibility, whether your aim is to invest for the long term or to trade market moves over shorter periods. To help you choose the platform that fits your needs and minimizes fees, a detailed broker comparison is available further down the page.

Spot Buying

Cash or spot buying means purchasing actual shares of Seres Therapeutics that you will then own in your broker’s account. This method is ideal for investors seeking direct ownership and wishing to benefit from any share price appreciation in the long run. Typically, brokers charge a fixed commission per transaction, which for UAE investors is often around 15–25 AED (about $4–7 USD) per order.

Example

If the Seres Therapeutics share price is $7.09, a $1,000 investment allows you to buy about 140 shares ($1,000 – $5 fee = $995 / $7.09 ≈ 140 shares).
✔️ Gain scenario:
If the share price rises by 10%, your holding’s value grows to $1,100.
Result: That’s a $100 gross gain — or +10% on your initial investment.

Trading via CFD

CFDs (Contracts for Difference) are derivatives that allow you to speculate on Seres Therapeutics’ share price without owning the shares outright. With CFDs, you can apply leverage (borrowed capital), amplifying your market exposure — but also your risk. CFD brokers typically charge a spread (the difference between buy and sell prices) and overnight financing fees if your position is left open beyond the trading day.

Example

With a $1,000 deposit and 5× leverage, you control $5,000 worth of Seres Therapeutics shares.
✔️ Gain scenario:
If the share price rises by 8%, your position increases by 40% (8% × 5).
Result: That’s a $400 gain on your $1,000 margin (not counting fees). Remember: leverage increases both gains and possible losses.

Final Advice

Before investing in Seres Therapeutics, always compare brokers’ fees, execution quality, and service levels — especially for US stocks from the UAE. Deciding whether to buy shares outright or use CFDs depends on your risk tolerance, time horizon, and objectives. Ready to proceed? The best brokers on the UAE market are compared further down this page, so you can make an informed and confident choice for your investment journey.

Our 7 tips for buying Seres Therapeutics stock

The latest news about Seres Therapeutics

Seres Therapeutics posted a positive net income of $32.7 million in Q1 2025, exceeding expectations. This exceptional quarterly profit, a reversal from a $32.9 million loss in Q1 2024, was fueled by a $50 million milestone payment from Nestlé following the sale of VOWST. While the operational revenue stream remains dormant, the strong non-recurring income has significantly boosted the company’s financial runway and supports ongoing clinical development activities, which is particularly relevant for institutional investors from AE seeking U.S. biotech exposure with recent fiscal upside.

On May 30, 2025, Seres confirmed financial stability until Q1 2026, thanks to Nestlé payments and current cash reserves. The company reported $58.8 million in cash as of March 31, 2025, with another $25 million expected from Nestlé in July 2025. This robust liquidity profile underpins the anticipated commencement of the Phase 2 clinical trial for SER-155 and provides solid financial visibility for at least three quarters, reducing near-term refinancing risks – making the stock a more attractive, lower-risk opportunity for AE-based long-horizon or strategic biotech investors.

The company’s lead asset, SER-155, achieved FDA Breakthrough Therapy Designation, underscoring its innovation and growth potential. Granted in December 2024 for its ability to reduce bloodstream infections in post-allogeneic hematopoietic cell transplantation patients, SER-155 stands out in the high-potential field of live microbiome therapeutics. Recent biomarker data were favorably presented at the ASCO Congress in May 2025, and a Phase 2 protocol is now being prepared for FDA submission. These advances strongly position Seres for future market expansion and potential strategic or commercial alliances, which could be especially relevant for AE healthcare sectors interested in cutting-edge immunology and infection prevention.

The company remains actively engaged in securing strategic partnerships to accelerate the development of its microbiome pipeline. Current corporate communications highlight an active search for partnerships around the SER-155 program, and management’s openness to collaborating on broader patient populations and indications. These efforts indicate strong business development momentum and could favorably impact shareholder value, a dynamic closely watched by international investors and regional healthcare innovation partners in the UAE.

Seres Therapeutics’ differentiated expertise in the field and previous success with VOWST open doors for further regional collaborations and licensing discussions in MEA markets. As the original developer of VOWST, the first FDA-approved oral microbiome therapy (now commercialized by Nestlé), Seres offers a proven track record in translating microbiome science to clinical and commercial outcomes. Given the increasing UAE strategic focus on healthcare innovation and advanced therapeutics adoption, Seres’ continued pipeline progress and willingness for global partnerships may present unique opportunities for AE-based stakeholders to engage in licensing, co-development, or market access discussions as new data emerge and regulatory approvals progress.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.